Eradication of Helicobacter pylori in Patients with S-2 Stage Duodenal Ulcer Scar an Interim Report.
- Author:
Jun Haeng LEE
;
Poong Lyul RHEE
;
Jae Geun HYUN
;
Won Hyeok CHOE
;
Yun Jeong LIM
;
Byeong Hoon AHN
;
Yong Wook LEE
;
Young Ho KIM
;
Jae J KIM
;
Kwang Cheol KOH
;
Seung Woon PAIK
;
Jong Chul RHEE
;
Kyoo Wan CHOI
- Publication Type:Original Article
- MeSH:
Amoxicillin;
Cicatrix*;
Clarithromycin;
Duodenal Ulcer*;
Endoscopy;
Follow-Up Studies;
Helicobacter pylori*;
Helicobacter*;
Humans;
Omeprazole;
Peptic Ulcer;
Prospective Studies;
Stomach Ulcer;
Ulcer
- From:Korean Journal of Gastrointestinal Endoscopy
2002;24(2):71-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: It is recommended that duodenal ulcer patients who are infected with H. pylori should be treated with eradication therapy, whether the ulcer is active or in remission. However, there has been no report on the effect of eradication treatment in patients with incidentally found S-2 stage duodenal ulcer scar. METHODS: We prospectively enrolled 80 H. pylori-positive patients with S-2 stage duodenal ulcer scar who have no past history of ulcer treatment. Treatment group received triple therapy consisted of omeprazole, amoxicillin, and clarithromycin for 2 weeks, whereas control group received no treatment. The follow-up endoscopy was performed every 1 year and when the patients have symptoms of ulcer disease. Fifty-three patients were followed up for more than 1 year. RESULTS: The eradication rate of the treatment group was 92.9%. During the follow-up period of 14.7 months, 20% (5/25) of patients in the control group (2 gastric ulcers and 3 duodenal ulcers) and 3.6% (1/28) of patients in the treatment group (1 duodenal ulcer) developed active or healing stage peptic ulcers (p=0.089). CONCLUSIONS: Our results suggest that H. pylori eradication may he effective in preventing peptic ulcers in patients with S-2 stage duodenal ulcer scar.
